Newman et al. review the evolving landscape of antibody-drug conjugates (ADCs) in breast cancer, including approved agents, resistance mechanisms, and combinatorial strategies. The authors highlight novel agents, antigen targets, and next-generation platforms, underscoring the need for predictive biomarkers and optimized sequencing strategies to improve patient selection and efficacy.
Radically different